Current Cardiology Reports

, 17:72 | Cite as

Cannabis, Cannabinoids, and Cerebral Metabolism: Potential Applications in Stroke and Disorders of the Central Nervous System

  • Julius Gene S. LatorreEmail author
  • Elena B. Schmidt
Stroke (D Wang, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Stroke


No compound has generated more attention in both the scientific and recently in the political arena as much as cannabinoids. These diverse groups of compounds referred collectively as cannabinoids have both been vilified due to its dramatic and potentially harmful psychotropic effects and glorified due to its equally dramatic and potential application in a number of acute and chronic neurological conditions. Previously illegal to possess, cannabis, the plant where natural form of cannabinoids are derived, is now accepted in a growing number of states for medicinal purpose, and some even for recreational use, increasing opportunities for more scientific experimentation. The purpose of this review is to summarize the growing body of literature on cannabinoids and to present an overview of our current state of knowledge of the human endocannabinoid system in the hope of defining the future of cannabinoids and its potential applications in disorders of the central nervous system, focusing on stroke.


Cannabinoid Stroke Cannabis Neuroprotection Ischemia Endocannabinoids 


Compliance with Ethics Guidelines

Conflict of Interest

Julius Gene S. Latorre and Elena B. Schmidt declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.••
    Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol. 2006;147 Suppl 1:S163–71. This paper provides a historical perspective on the discovery of cannabinoids, cannabinoid pharmacology, and its potential application in health and disease.Google Scholar
  2. 2.
    Mechoulam R. Looking back at cannabis research. Curr Pharm Des. 2000;6(13):1313–22.CrossRefPubMedGoogle Scholar
  3. 3.
    El-Alfy AT et al. Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacol Biochem Behav. 2010;95(4):434–42.CrossRefPubMedCentralPubMedGoogle Scholar
  4. 4.
    Devane WA et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258(5090):1946–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Mechoulam R et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 1995;50(1):83–90.CrossRefPubMedGoogle Scholar
  6. 6.
    Seely KA et al. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39(2):234–43.CrossRefPubMedCentralPubMedGoogle Scholar
  7. 7.••
    Maccarrone M et al. Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci. 2015;36(5):277–96. This review provides an overview of the discovery of the endocannabinoid system (ECS). In addition, it reviews the potential therapeutic applications of ECS as well as emerging challenges and gaps in knowledge in cannabinoid research.Google Scholar
  8. 8.
    Pertwee RG et al. International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2). Pharmacol Rev. 2010;62(4):588–631.CrossRefPubMedCentralPubMedGoogle Scholar
  9. 9.
    Matsuda LA et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346(6284):561–4.CrossRefPubMedGoogle Scholar
  10. 10.••
    Stanley C, O’Sullivan SE. Vascular targets for cannabinoids: animal and human studies. Br J Pharmacol. 2014;171(6):1361–78. This review provides an excellent summary of animal and human in vitro studies on sites of action and vascular targets for cannabinoids and similar compounds.Google Scholar
  11. 11.
    Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365(6441):61–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Atwood BK, Mackie K. CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol. 2010;160(3):467–79.CrossRefPubMedCentralPubMedGoogle Scholar
  13. 13.
    Kim SH et al. Molecular mechanisms of cannabinoid protection from neuronal excitotoxicity. Mol Pharmacol. 2006;69(3):691–6.PubMedGoogle Scholar
  14. 14.•
    Pacher P, Hasko G. Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. Br J Pharmacol. 2008;153(2):252–62. This review summarizes the role of endocannabinoids and cannabinoid receptors in various forms of ischemia-reperfusion injury and preconditioning.Google Scholar
  15. 15.
    Aguado T et al. The CB1 cannabinoid receptor mediates excitotoxicity-induced neural progenitor proliferation and neurogenesis. J Biol Chem. 2007;282(33):23892–8.CrossRefPubMedGoogle Scholar
  16. 16.
    van der Stelt M, Di Marzo V. Cannabinoid receptors and their role in neuroprotection. Neuromolec Med. 2005;7(1–2):37–50.CrossRefGoogle Scholar
  17. 17.
    Ralevic V et al. Cannabinoid modulation of sensory neurotransmission via cannabinoid and vanilloid receptors: roles in regulation of cardiovascular function. Life Sci. 2002;71(22):2577–94.CrossRefPubMedGoogle Scholar
  18. 18.•
    Capettini LS et al. Update on the role of cannabinoid receptors after ischemic stroke. Mediat Inflamm. 2012;2012:824093. This paper provides an updated review of the current available evidence on the neuroprotective properties of cannabinoids after ischemic stroke in humans and animal models.Google Scholar
  19. 19.
    Freedland CS et al. Dose-dependent effects of Delta9-tetrahydrocannabinol on rates of local cerebral glucose utilization in rat. Synapse. 2002;45(2):134–42.CrossRefPubMedGoogle Scholar
  20. 20.
    Whitlow CT, Freedland CS, Porrino LJ. Functional consequences of the repeated administration of Delta9-tetrahydrocannabinol in the rat. Drug Alcohol Depend. 2003;71(2):169–77.CrossRefPubMedGoogle Scholar
  21. 21.
    Stanley CP, Hind WH, O’Sullivan SE. Is the cardiovascular system a therapeutic target for cannabidiol? Br J Clin Pharmacol. 2013;75(2):313–22.CrossRefPubMedCentralPubMedGoogle Scholar
  22. 22.•
    Hillard CJ. Role of cannabinoids and endocannabinoids in cerebral ischemia. Curr Pharm Des. 2008;14(23):2347–61. This paper provides the hypothesized mechanisms involved in the neuroprotective effects of cannabinoid receptor activation or inhibition.Google Scholar
  23. 23.
    Sun S et al. Pharmacologically induced hypothermia with cannabinoid receptor agonist WIN55, 212–2 after cardiopulmonary resuscitation. Crit Care Med. 2010;38(12):2282–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Ma L et al. Improved cardiac and neurologic outcomes with postresuscitation infusion of cannabinoid receptor agonist WIN55, 212–2 depend on hypothermia in a rat model of cardiac arrest. Crit Care Med. 2014;42(1):e42–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Fernandez-Lopez D et al. Cannabinoids: well-suited candidates for the treatment of perinatal brain injury. Brain Sci. 2013;3(3):1043–59.CrossRefPubMedCentralPubMedGoogle Scholar
  26. 26.
    Murikinati S et al. Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. FASEB J. 2010;24(3):788–98.CrossRefPubMedGoogle Scholar
  27. 27.
    Fernandez-Lopez D et al. Reduced infarct size and accumulation of microglia in rats treated with WIN 55,212-2 after neonatal stroke. Neuroscience. 2012;207:307–15.CrossRefPubMedCentralPubMedGoogle Scholar
  28. 28.
    Suzuki N et al. Cerebroprotective effects of TAK-937, a cannabinoid receptor agonist, on ischemic brain damage in middle cerebral artery occluded rats and non-human primates. Brain Res. 2012;1430:93–100.CrossRefPubMedGoogle Scholar
  29. 29.
    Sommer C et al. Neuroprotective cannabinoid receptor antagonist SR141716A prevents downregulation of excitotoxic NMDA receptors in the ischemic penumbra. Acta Neuropathol. 2006;112(3):277–86.CrossRefPubMedGoogle Scholar
  30. 30.
    Zhang M et al. Modulation of the balance between cannabinoid CB(1) and CB(2) receptor activation during cerebral ischemic/reperfusion injury. Neuroscience. 2008;152(3):753–60.CrossRefPubMedCentralPubMedGoogle Scholar
  31. 31.
    Zarruk JG et al. Cannabinoid type 2 receptor activation downregulates stroke-induced classic and alternative brain macrophage/microglial activation concomitant to neuroprotection. Stroke. 2012;43(1):211–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Molina-Holgado F et al. CB2 cannabinoid receptors promote mouse neural stem cell proliferation. Eur J Neurosci. 2007;25(3):629–34.CrossRefPubMedGoogle Scholar
  33. 33.
    Downer EJ. High hopes for CB(2) receptors in neurogenesis. Br J Pharmacol. 2014;171(6):1345–6.CrossRefPubMedCentralPubMedGoogle Scholar
  34. 34.
    Palazuelos J et al. Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J. 2006;20(13):2405–7.CrossRefPubMedGoogle Scholar
  35. 35.
    Maas AI et al. Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurol. 2006;5(1):38–45.CrossRefPubMedGoogle Scholar
  36. 36.
    Wolff V et al. Cannabis use, ischemic stroke, and multifocal intracranial vasoconstriction: a prospective study in 48 consecutive young patients. Stroke. 2011;42(6):1778–80.CrossRefPubMedGoogle Scholar
  37. 37.
    Wolff V et al. High frequency of intracranial arterial stenosis and cannabis use in ischaemic stroke in the young. Cerebrovasc Dis. 2014;37(6):438–43.CrossRefPubMedGoogle Scholar
  38. 38.
    Seely KA et al. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Mol Interv. 2011;11(1):36–51.CrossRefPubMedCentralPubMedGoogle Scholar
  39. 39.
    Pertwee RG. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci. 2012;367(1607):3353–63.CrossRefPubMedCentralPubMedGoogle Scholar
  40. 40.
    Devinsky O et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014;55(6):791–802.CrossRefPubMedGoogle Scholar
  41. 41.
    Bergamaschi MM et al. Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf. 2011;6(4):237–49.CrossRefPubMedGoogle Scholar
  42. 42.
    Ignatowska-Jankowska BM et al. In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects. Br J Pharmacol. 2014;171(6):1392–407.CrossRefPubMedCentralPubMedGoogle Scholar
  43. 43.
    Jesudason D, Wittert G. Endocannabinoid system in food intake and metabolic regulation. Curr Opin Lipidol. 2008;19(4):344–8.CrossRefPubMedGoogle Scholar
  44. 44.
    Pavon FJ et al. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats. J Neuroendocrinol. 2008;20 Suppl 1:116–23.CrossRefPubMedGoogle Scholar
  45. 45.
    Addy C et al. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab. 2008;7(1):68–78.CrossRefPubMedGoogle Scholar
  46. 46.
    Zuba D, Byrska B, Maciow M. Comparison of “herbal highs” composition. Anal Bioanal Chem. 2011;400(1):119–26.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Neurocritical Care Division, Department of Neurology and NeurosurgerySUNY Upstate Medical UniversitySyracuseUSA
  2. 2.Neurocritical Care Division, Departments of NeurologySUNY Upstate Medical UniversitySyracuseUSA

Personalised recommendations